Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests needed A new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results . Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of
A new weekly injection for type 2 diabetes, known as retatrutide, has demonstrated significant reductions in both blood sugar levels and body weight during a phase 3 clinical trial. Participants receiving the triple-action drug for 40 weeks experienced substantial weight loss, exceeding four times that of the placebo group. Additionally, the treatment led to a more than twofold greater decrease in long-term blood sugar (HbA1c) compared to placebo.
Retatrutide functions by mimicking three key gut hormones—GLP-1, GIP, and glucagon—which play crucial roles in appetite regulation, blood sugar control, and metabolism. This approach differs from existing diabetes medications by also activating the glucagon receptor, a mechanism believed to boost energy expenditure.
This development offers a promising new therapeutic option for managing type 2 diabetes and obesity, potentially improving patient outcomes through a novel multi-hormonal approach.
📌 Kaynak
Bu özet Guardian World kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →